3D DNA double helix with a highlighted red DNA sequence representing genetic research and oligonucleotide synthesis.

Custom Oligonucleotide Synthesis Services: A Complete Guide for Researchers

Oligonucleotides play an important role in modern molecular biology, pharmaceutical research, biotechnology, and molecular diagnostics. From amplifying specific DNA regions to analyzing gene expression and studying genetic variations, these short nucleic acid sequences support a wide range of laboratory applications. However, not every research experiment requires the same type of oligonucleotide. Sequence, length, purification, synthesis…

Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs

REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs

REPROCELL and Polyphron Announce Collaboration to Advance AI-Driven Human Tissue Research Using StemRNA™ iPSCs Yokohama, Japan / Long Island City, NY – [September 28th,2026] — REPROCELL (Yokohama, Japan; TYO: 4978) and Polyphron, Inc. (Long Island City, NY) are pleased to announce their collaboration under which REPROCELL will supply its proprietary StemRNA™ iPSCs for use across…

REPROCELL Expands Clinical iPSC and Stem Cell Solutions in China Through Strategic Collaboration with WEIPU Biotechnology

Yokohama, Japan / Suzhou, China – July 27, 2026 – REPROCELL Inc., a global provider of clinical-grade iPSC technologies and regenerative medicine solutions, today announced a strategic collaboration with WEIPU Biotechnology Co., Ltd., a biotechnology company based in Suzhou, China, to support cell therapy developers in China with access to high-quality clinical starting materials and…

REPROCELL Submits Application for Manufacturing and Marketing Approval in Japan for Stem Cell Therapy Stemchymal® for Spinocerebellar Ataxia (SCA3 and SCA6)

JAPAN, June 24, 2026 – REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal®, for which the company holds exclusive commercialization rights in Japan. The application seeks approval for the use of Stemchymal® to suppress the progression of ataxia in patients with…

AI-Designed CRISPR Enables Hypoimmune iPSC Engineering for Off-the-Shelf Cell Therapy

Induced pluripotent stem cells (iPSCs) are rapidly advancing regenerative medicine and cell therapy because they can differentiate into multiple human cell types. However, immune rejection remains a major barrier to developing scalable allogeneic cell therapies. In a recent webinar, Dr. Luke Ren from REPROCELL presented how the company is using StemEdit, its advanced gene editing…

Key Steps in Custom DNA Oligonucleotide Synthesis

What Is Custom DNA Oligonucleotide Synthesis? Custom DNA oligonucleotide synthesis is the chemical process of building short, single-stranded DNA sequences—called oligonucleotides or “oligos”—in a controlled, laboratory setting. These synthetic DNA molecules are indispensable tools in modern molecular biology, genomics, diagnostics, and therapeutic development. Whether you are designing primers for PCR amplification, probes for next-generation sequencing…

Bioserve – A REPROCELL Company Launches GMP Master Cell Bank Manufacturing for Clinical iPSCs

Integrated Workflow Including Clinical Seed Production and StemEdit Gene Editing Services Beltsville, MD, USA / Yokohama, Japan – 3rd March 2026 Bioserve – A REPROCELL Company proudly announces the launch of US FDA-compliant Good Manufacturing Practice (GMP) Master Cell Bank (MCB) manufacturing services for human induced pluripotent stem cells (iPSCs), now available to support global…

Major Global News & Breakthroughs in Stem Cell Research

Stem cell research has entered a decisive translational era. Breakthroughs in induced pluripotent stem cell (iPSC) technology and precision gene editing are rapidly converting experimental concepts into clinically validated therapies. What were once proof-of-concept studies are now progressing through late-stage clinical trials and, in some cases, delivering first-in-human successes. These advances are unlocking new therapeutic frontiers…